# OnCo record pancreatic-cancer-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/pancreatic-cancer-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "pancreatic-cancer-signalling" ;
  schema:name "Pancreatic cancer (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05212"@en, "Pancreatic cancer"@en ;
  schema:description "This KEGG map shows the order of genetic hits that turn normal pancreatic duct cells into ductal adenocarcinoma: KRAS mutation first, then loss of the p16 brake, then loss of TP53, SMAD4 and BRCA2. It matters because nearly every pancreatic cancer is driven by KRAS, which until recently had no drug."@en ;
  schema:url <https://onco.cc/pathways/pancreatic-cancer-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05212>, <https://doi.org/10.1038/nrdp.2016.22> ;
  onco:related <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/ddr/>, <https://onco.cc/pathways/tgf-beta/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/> ;
  onco:targets <https://onco.cc/targets/her2/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/pik3ca/>, <https://onco.cc/targets/jak2/>, <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/brca/>, <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/adagrasib/>, <https://onco.cc/drugs/daraxonrasib/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/erlotinib/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/pi3k-akt-mtor/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/tgf-beta/>, <https://onco.cc/pathways/ddr/>, <https://onco.cc/pathways/jak-stat/>, <https://onco.cc/pathways/rtk-activation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-kleeff-nat-rev-dis-primers/> .